NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
NeuroSense's Nasdaq Hearings Panel appeal is scheduled for November 10, 2026, following the October 1 Staff Delisting Determination; shares and warrants continue trading under NRSN and NRSNW pending the Panel's decision. The company has already regained compliance with the $1.00 minimum bid price requirement, leaving the $35 million minimum market value of listed securities standard as the sole remaining deficiency. NeuroSense will present a plan to meet that standard or the alternative $2.5 million stockholders' equity requirement, and will request an exception period of up to 180 days.
Key figures
- Hearing date
- November 10, 2026
- Grant funding decision
- Q1 2027
- Minimum mvx requirement
- $35 million
- Health canada nda target
- December 2026
- Staff determination date
- October 1, 2026
- Max exception period days
- 180
- Alternative stockholders equity standard
- $2.5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.